Document ER8nL1q1GLBZnmoj3nN7daXb

CorporatOeccupationMaeldicine 3M CenterB,uildin2g20-3W-05 St.PaulM,N 55144-1000 6517374230Telephone 6517339066Fax 9.PhysiciaPnlantSummary ReportsRegardingMedicalSurveillanPcreogram atCottageGrove (1978-1991) Followinrgeportosfthefindinogforganifcluorinienserasamplesa,fluorochemical medical surveillancperogram began at3M's manufacturingfacilitiiensthemid 1970's. The surveillanceprogram has generallyconsistedof annualor biannualtestsof clinical chemistriesp,ulmonary function,blood countsand a biomonitorof fluorochemical exposure.A totalorganicfluorinemeasurement was performeduntil1993. This measures the amount offluorinethatwas covalentlybound to carbon inthe serum sample. When testdatawere availablea,company physicianreviewed each employee's results.These physiciansdid not,and have not,found abnormalitiesinindividualtshat they feltwere relatedtofluorochemicalexposure. Attached are 7 reportswrittenby 3M occupationalmedicine physiciansregarding medical surveillanceprogram resultsatthe Cottage Grove manufacturingsitewhere PFOA productswere manufactured. These reportsare: a. Blood levelsofRF/F [organictotalfluorine]inselectedemployees (6/20/78) b. 1981 chemicaldivisionhealthevaluation(s2/16/82) c. 1981 Chemolite healthevaluation(s8/12/82) d. Inorganicfluoriddeetermination(s4/9/84) e. Organic fluoridleevels(8/31/84) f Medicalexaminations(3/20/87) g. Chemoliteexaminations(5/10/91)